Episode 400: 408. CME Obesity and MASH

Episode 400: 408. CME Obesity and MASH

  • GLP1 drugs work but they likely need lifestyle modifications


  • No convincing evidence GLP1 cause thyroid cancer in humans BUT contraindication if family history exist


  • Stopping therapy usually results in weight gain


  • Insurance coverage for weight loss is limited and variable


  • Semaglutide for type 2 diabetes max dose is 2.0 mg weekly Semaglutide for weight loss has a goal dose of 2.4 mg weekly
  • Diagnose steatotic liver disease with imaging and 1 metabolic risk factor (or biopsy)


  • After diagnosis check FIB-4:
    • Low risk, continue to monitor with FIB-4 every 2-3yrs
    • Intermediate risk, order VCTE and consider referral if >F1
    • High risk order a VCTE and referral (20% end with SLD)


  • 2 FDA approved medications for liver fibrosis are not cheap, expect insurance push back


Avsnitt(388)

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
rss-jossan-nina
inga-beiga-morsor
rss-vuxna-pa-latsas
angestpodden
johannes-hansen-podcast
not-fanny-anymore
rss-viktmedicinpodden
sexnoveller-deluxe
sa-in-i-sjalen
alska-oss
sova-med-dan-horning
brottarbroder
rss-sjalsligt-avkladd
tyngre-radio
tyngre-traningssnack
rss-basta-livet
smartare-fitness-podden
rss-livet-pagar-din-coachningpodcast